ARUP's Laboratory Test Directory

Haptoglobin (HP) Genotyping : 0040116
[ image for: Consent Form Recommended]
Consent Form Recommended
[ image for: Additional Technical Information]
Additional Technical Information


Mnemonic: HAPTO PCR

Ordering Recommendation: Assess genetic risk for coronary artery disease.
Methodology: Polymerase Chain Reaction/Fluorescence Monitoring
Performed: Mon, Thu
Reported: 2-7 days
Specimen Required: Collect: Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature: Refrigerated.

Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Reference Interval:
By report
Interpretive Data: Interpretive Data:
Background Information for Haptoglobin (HP) Genotyping:
Characteristics: Hp genotype is a predictor of cardiovascular disease in diabetic patients. There is no known correlation between the Hp genotype and cardiovascular risk in nondiabetics. Diabetics with the Hp 2-2 genotype are five times more likely to have cardiovascular disease than those with the Hp 1-1 genotype and may benefit from vitamin E treatment. Diabetics who have the Hp 1-1 genotype are at decreased risk for developing microvascular complications such as nephropathy, retinopathy or for restenosis following percutaneous coronary angioplasty.
Incidence: The Hp 1 and Hp 2 allele frequencies vary across populations. Asians have the highest frequency of Hp 2. The Hp 2-2 genotype is 36 percent in Northwestern Europeans.
Inheritance: Autosomal recessive.
Alleles Tested: Hp 1 and Hp 2.
Clinical Sensitivity: Unknown.
Methodology: Polymerase chain reaction and fluorescence monitoring.
Analytical Sensitivity and Specificity: 98 percent.
Limitations: Rare diagnostic errors may occur due to primer site mutations. Anhaptoglobinemia (Hp0-0) or hypohaptoglobinemia (Hp 1-0 or Hp 2-0) may be misclassified depending on the cause of lack of gene expression.

This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.
This test is performed pursuant to an agreement with Synvista, Inc.



Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.

See Compliance Statement C: www.aruplab.com/CS
Note: This test is not recommended for the assessment of cardiovascular risk in nondiabetics as there is poor evidence of a correlation between the genotype and cardiovascular risk.
CPT Code(s): 81479